Home Cart Sign in  
Chemical Structure| 118525-40-9 Chemical Structure| 118525-40-9

Structure of Icaritin
CAS No.: 118525-40-9

Chemical Structure| 118525-40-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Icaritin is a flavonoid that can enhance osteoblastic differentiation of mesenchymal stem cells (MSCs) and display a role of estrogen-like activities. Icaritin could be extracted from the roots of Epimedium brevicornu Maxim with anti-cancer effects.

Synonyms: Anhydroicaritin; Cycloicaritin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Icaritin

CAS No. :118525-40-9
Formula : C21H20O6
M.W : 368.38
SMILES Code : O=C1C(O)=C(OC2=C(C(O)=CC(O)=C12)C/C=C(C)\C)C3=CC=C(C=C3)OC
Synonyms :
Anhydroicaritin; Cycloicaritin
MDL No. :MFCD22422519
InChI Key :TUUXBSASAQJECY-UHFFFAOYSA-N
Pubchem ID :5318980

Safety of Icaritin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT-29 cells 20 μM 36 hours Icaritin inhibited the formation of CDK2/cyclin E complex, reduced CDK2 activity, leading to attenuated phosphorylation of FOXO1, Rb, and P27, and E2F/Rb dissociation PMC9460166
PLC cells 20 μM 36 hours Icaritin inhibited the formation of CDK2/cyclin E complex, reduced CDK2 activity, leading to attenuated phosphorylation of FOXO1, Rb, and P27, and E2F/Rb dissociation PMC9460166

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01972672 Hepatocellular Carcinoma (HCC) PHASE2 COMPLETED 2025-03-17 Cancer institute & hospital, c... More >>hinese academy of medical sciences, Beijing, Beijing, 100021, China|Beijing Shenogen Biomedical Co., Ltd, Beijing, Beijing, 102206, China|NanJing PLA 81 Hospital, Nanjing, Jiangsu, 210002, China Less <<
NCT02496949 Solid Tumors PHASE1 COMPLETED 2025-08-13 Cancer institute & hospital, c... More >>hinese academy of medical sciences, Beijing, Beijing, 100021, China Less <<
NCT06285149 HCC PHASE2 NOT_YET_RECRUITING 2025-06-01 -
NCT01278810 Metastatic Breast Cancer PHASE1 UNKNOWN 2025-12-11 Cancer institute & hospital, c... More >>hinese academy of medical sciences, Beijing, Beijing, 100021, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.57mL

2.71mL

1.36mL

27.15mL

5.43mL

2.71mL

References

 

Historical Records

Categories